UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) July 1, 2003
----------------
Generex Biotechnology Corporation
--------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 000-25169 98-0178636
---------------------------- ----------- ------------------
(State or other jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
33 Harbor Square, Suite 202, Toronto, Ontario Canada M5J 2G2
---------------------------------------------------- ----------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code 416/364-2551
--------------
--------------------------------------------------------------------------------
(Former name or former address, if changed since last report)
Item 4. Changes in Registrant's Certifying Accountant.
Effective July 1, 2003 Generex Biotechnology Corporation dismissed Deloitte &
Touche, LLP ("Deloitte") and engaged BDO Dunwoody, LLP ("BDO Dunwoody") to serve
as the independent public accountants to audit the financial statements Generex
for the fiscal year ending July 31, 2003.
The appointment of BDO Dunwoody as independent public accountants replacing
Deloitte was approved by the audit committee of Generex's Board of Directors.
Deloitte did not decline to stand for re-election.
Deloitte's reports on Generex's financial statements for the last two fiscal
years did not contain an adverse opinion or a disclaimer of opinion, and was not
qualified or modified as to uncertainty, audit scope or accounting principles.
During our past two fiscal years, and the subsequent interim period preceding
Deloitte's dismissal, we had no disagreements with Deloitte, as the term
"disagreement" is defined in Item 304(a)(1)(iv) of Regulation S-K, on any matter
of accounting principles or practices, financial statement disclosure, or
auditing scope or procedure which disagreements, if not resolved to Deloitte's
satisfaction, would have caused Deloitte to make reference to the subject matter
of the disagreements in its reports. During our past two fiscal years, and the
subsequent interim period preceding Deloitte's dismissal, there were no
"reportable events" as that term is defined in Item 304 (a)(1)(v) of Regulation
S-K.
Effective July 1, 2003, we engaged BDO Dunwoody as our independent public
accountants. During the past two fiscal years, we have had no consultations with
BDO Dunwoody concerning: (a) the application of accounting principles to a
specific transaction or the type of opinion that might be rendered on our
financial statements, as to which a written report was provided to us or as to
which we received oral advice from BDO Dunwoody, that BDO Dunwoody concluded was
an important factor in reaching a decision on any accounting, auditing or
financial reporting issue; or (b) any matter that was the subject of a
disagreement or a reportable event, as those terms are defined in Item
304(a)(1)(iv) and (v) of Regulation S-K.
Item 7. Financial Statements and Exhibits
16. Letter from Deloitte & Touche, LLP regarding its concurrence with the
statements made by Generex in this Report regarding its dismissal as
principal accountant.
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
GENEREX BIOTECHNOLOGY CORPORATION
Dated: July 1, 2003 By: Rose Perri
--------------------------
Rose Perri
Chief Operating Officer
2